Deutsche Bank AG Increases Stake in Fluidigm Co. (FLDM)

Deutsche Bank AG lifted its holdings in Fluidigm Co. (NASDAQ:FLDM) by 43.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 173,263 shares of the medical research company’s stock after acquiring an additional 52,547 shares during the quarter. Deutsche Bank AG’s holdings in Fluidigm were worth $1,493,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in Fluidigm by 739.4% in the third quarter. JPMorgan Chase & Co. now owns 72,339 shares of the medical research company’s stock valued at $542,000 after purchasing an additional 63,721 shares during the last quarter. Neuberger Berman Group LLC lifted its stake in Fluidigm by 0.5% in the third quarter. Neuberger Berman Group LLC now owns 4,535,180 shares of the medical research company’s stock valued at $33,971,000 after purchasing an additional 24,186 shares during the last quarter. Vanguard Group Inc. lifted its stake in Fluidigm by 9.5% in the third quarter. Vanguard Group Inc. now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after purchasing an additional 121,815 shares during the last quarter. Vanguard Group Inc lifted its stake in Fluidigm by 9.5% in the third quarter. Vanguard Group Inc now owns 1,410,526 shares of the medical research company’s stock valued at $10,565,000 after purchasing an additional 121,815 shares during the last quarter. Finally, Quantamental Technologies LLC purchased a new position in Fluidigm in the fourth quarter valued at approximately $61,000. 71.73% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently commented on the company. Zacks Investment Research downgraded Fluidigm from a “hold” rating to a “strong sell” rating in a research note on Friday, February 8th. BidaskClub upgraded Fluidigm from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 16th. Piper Jaffray Companies increased their target price on Fluidigm from $10.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. UBS Group initiated coverage on Fluidigm in a research report on Friday, March 15th. They set a “neutral” rating and a $14.00 target price on the stock. Finally, BTIG Research initiated coverage on Fluidigm in a research report on Wednesday, March 13th. They set a “buy” rating and a $15.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Fluidigm has a consensus rating of “Buy” and an average target price of $14.50.

NASDAQ:FLDM opened at $12.22 on Friday. The firm has a market cap of $811.42 million, a price-to-earnings ratio of -15.28 and a beta of 2.40. Fluidigm Co. has a 1 year low of $4.65 and a 1 year high of $14.90. The company has a current ratio of 3.38, a quick ratio of 3.04 and a debt-to-equity ratio of 2.39.

Fluidigm (NASDAQ:FLDM) last posted its earnings results on Thursday, May 2nd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.30). The company had revenue of $30.10 million for the quarter, compared to analysts’ expectations of $29.18 million. Fluidigm had a negative return on equity of 79.04% and a negative net margin of 60.45%. The business’s quarterly revenue was up 19.4% compared to the same quarter last year. On average, analysts predict that Fluidigm Co. will post -0.58 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Deutsche Bank AG Increases Stake in Fluidigm Co. (FLDM)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/deutsche-bank-ag-increases-stake-in-fluidigm-co-fldm.html.

Fluidigm Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Further Reading: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.